Corporate ProfileLa Jolla Pharmaceutical Company is a publicly traded biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases.
There are currently no items available.
La Jolla Pharmaceutical Company Announces Intent to Submit Marketing Authorization Application for LJPC-501 in the Third Quarter of 201809/25/17
-- Decision follows successful Scientific Advice meeting with European Medicines Agency -- SAN DIEGO--(BUSINESS WIRE)--Sep. 25, 2017-- La Jolla Pharmaceutical Company (NASDAQ:LJPC) (the Company or La Jolla) toda
Prespecified Analysis of ATHOS-3 Indicates Survival Benefit in LJPC-501-Treated Patients with Relatively Low Angiotensin II State09/20/17
Analysis to Be Presented in Oral Session at the 30th Annual Congress of The European Society of Intensive Care Medicine SAN DIEGO--(BUSINESS WIRE)--Sep. 20, 2017-- La Jolla Pharmaceutical Company (NASDAQ: LJPC) (the Co
La Jolla Pharmaceutical Company Announces U.S. FDA Acceptance of New Drug Application for LJPC-50108/28/17
– Priority Review Granted – SAN DIEGO--(BUSINESS WIRE)--Aug. 28, 2017-- La Jolla Pharmaceutical Company (NASDAQ: LJPC) (the Company or La Jolla) today announced that the U.S. Food and Drug Administration (FDA) h
|Print Page E-mail Page RSS Feeds E-mail Alerts IR Contacts|